The ductus arteriosus is a specialized blood vessel containing highly differentiated and contractile vascular smooth muscle, derived largely from neural crest cells, that is essential for fetal life but typically closes after birth. Impaired development of the ductus arteriosus or disruption of signaling pathways that initiate postnatal closure can result in persistent patency of the ductus arteriosus, the third most common congenital heart defect. We found that Tfap2␤, a transcription factor associated with patent ductus arteriosus in humans, was uniquely expressed in mouse ductal smooth muscle. Endothelin-1 and the hypoxia-induced transcription factor, Hif2␣ were also highly enriched in ductal smooth muscle at embryonic day 13.5 and were dependent on Tfap2␤ for their expression in this domain. Hif2␣ functioned as a negative regulator of Tfap2␤-induced transcription by disrupting protein-DNA interactions, suggesting a negative feedback loop regulating Tfap2␤ activity. Our data indicate that Tfap2␤, Et-1, and Hif2␣ act in a transcriptional network during ductal smooth muscle development and that disruption of this pathway may contribute to patent ductus arteriosus by affecting the development of smooth muscle within the ductus arteriosus. (Circ Res. 2008;103:388-395.)
N eural crest cells contribute to many embryonic structures and are among the first cells to differentiate into smooth muscle of the bilaterally symmetrical aortic arch arteries during cardiovascular development. 1 On extensive remodeling and contributions from progenitors of the second heart field, 2 the left sixth aortic arch artery contributes to a specialized vessel known as the ductus arteriosus (DA). The DA contains 1 of the most highly differentiated and contractile vascular smooth muscles. 3 Mammalian fetal circulation relies on this specialized vessel for blood to bypass the uninflated lung and enter the systemic circulation where oxygenation ultimately occurs in the placenta (Figure 1 ). At birth, closure of the DA separates the pulmonary and systemic circulations so that fully oxygenated blood is delivered to all of the organs after gas exchange in the lungs. Closure involves oxygen sensing by the specialized smooth muscle cells (SMCs) of the DA and a response to decreased circulating levels of the vasodilating hormone prostaglandin E 2 . Failure of this process results in patent ductus arteriosus (PDA), the third most common form of congenital heart disease in humans. 4 Although physiology of the DA has been well described, little is known about the transcriptional pathways that control development of its unique smooth muscle. In humans, PDA is associated with DNA-binding mutations in the gene encoding the neural crest-enriched transcription factor TFAP2␤, however the mechanism for the ductal abnormality is unknown. 5, 6 Although TFAP2␤ mutations are likely a rare cause of isolated PDAs, genetic causes of syndromic disease often provide unique insight into mechanisms of common disease. In mice, targeted deletion of Tfap2␤ causes apoptosis of renal epithelial cells and postnatal lethality, possibly attributable to polycystic kidney disease. 7 However, the effects on the DA have not been described.
Endothelin-1 (Et-1) may also play a role in the development of ductal smooth muscle (DSM). Et-1 is a 21 amino acid signaling peptide generally expressed in and secreted from vascular endothelial cells. Cleavage of the proform of Et-1 by the endothelin converting enzyme allows it to bind to its receptor, Et A , expressed in adjacent vascular SMCs. 8 Et A signaling is required for development of neural crest-derived structures, as targeted deletion of any of the components of the Et A signaling pathway results in craniofacial, outflow tract, and aortic arch abnormalities. 9 -11 Et A signaling is important for differentiation of the neural crest-derived smooth muscle in the aortic arch and pharyngeal arches. 12, 13 Many studies also support a role for endothelin signaling in oxygen-induced constriction of the DA. 14 -16 For example, in lambs, Et-1 release from ductal SMCs during the perinatal period is associated with constriction of the vessel at birth, 17 although its role in humans remains controversial.
Hypoxia-inducible factors (Hifs), which are basic helixloop-helix (bHLH)/PAS domain-containing transcription factors, are stabilized during hypoxia and imported to the nucleus, where they become activated, heterodimerize with Arnt, another bHLH/PAS domain containing protein, and bind DNA to regulate the transcription of target genes. 18 In addition to regulating oxygen-sensitive cellular events, Hifs are required for closure of the ductus venosus, a hepatic fetal vessel, at birth. 19 However, the potential function of Hifs in the DA has not been explored.
We found that Tfap2␤ was enriched in DSM of the fetal mouse. Hif2␣ and Et-1 were similarly enriched in embryonic DSM and relied on Tfap2␤ for transcriptional activation in this domain. Hif2␣ functioned in a negative feedback loop regulating Tfap2␤ activity consistent with the dosesensitivity of TFAP2␤ in humans. The findings here suggest that a regulatory cascade involving Tfap2␤, Hif2␣, and Et-1 is involved in the specialized development of DSM cells and, consequently, regulation of fetal circulation in mammals.
Materials and Methods

Immunochemistry
Immunohistochemistry was performed following antigen retrieval in citrate solution (Biogenex) with Tfap2␤ antibody (Santa Cruz, 1:100 in PBS), biotinylated ␣-rabbit IgG (1:200 in PBS), streptavidin-HRP and diaminobenzidine chromagen (Vector Labs). Sections were counterstained with Mayer's hematoxylin.
Luciferase Reporter Assays
Luciferase assays were performed in human umbilical vein endothelial cells (HUVECs) or A10 cells (ATCC) transfected with indicated plasmids and LacZ expression vector using Fugene6 (Roche). The total amount of transfected DNA was held constant using empty vector. The reporter construct (kindly provided by N. Bishopric) consisted of a 669 bp Et-1 promoter cloned upstream of luciferase. Assays were performed using the Luciferase Assay System (Promega). Results were normalized to ␤-gal activity detected with an o-nitrophenyl-galactopyranoside assay protocol. 20 Each transfection was performed a minimum of three times, and results are shown with standard deviations.
Embryo Harvesting and Histology
The care and use of animals were in accordance with institutional guidelines. Tfap2␤ ϩ/Ϫ mice were generated by M. Moser, Max-Planck Institute of Biochemistry, Martinsreid, Germany. Mice of the appropriate genotype were intercrossed, and embryos or pups were collected at the indicated time and fixed in 4% paraformaldehyde overnight at 4°C. Genotype was determined by PCR. 7, 10, 21 Specimens were paraffin embedded and sectioned transversely. Surrounding landmarks were used to confirm comparable section angles. Hif2␣ ϩ/LacZ21 embryos were harvested, fixed, and stained for ␤-gal activity. 22 Radioactive In Situ Hybridization 35 S-Labeled antisense probes were synthesized from partial cDNAs of Hif2␣, Tfap2␤, Et-1, Et A , or calponin. cDNAs were linearized and transcribed with the following restriction enzymes and RNA polymerases: Hif2␣, BamHI, SP6; Tfap2␤, XbaI, T7; Et-1, EcoRV; SP6; Et A , Pst1; SP6; calponin. 23 Radioactive section in situ hybridization was performed on paraffin mouse sections as described. 24 
Transfections, Chloramphenicol Acetyltransferase Assays, and Western Blot Analysis
Transfections and CAT assays were performed as described. 5 Each transfection was performed a minimum of three times, and results are shown with standard deviations. Tfap2␤ protein levels were measured by western analysis of cell lysates using a Tfap2␤ antibody, HRP-conjugated donkey anti-rabbit IgG, and Western Blotting Luminol Reagent (Santa Cruz Biotechnology).
Electrophoretic Mobility-Shift Assays
Oligonucleotides were synthesized (Integrated DNA Technologies) as follows: control, 5Ј-GGGATCGAACTGACCGCCCGCGGC CCGT-3Ј and 5Ј-GGGACGGGCCGCGGGCGGTCAGTTCGATC-3Ј; mutant, 5Ј-GGGATTGTCAGACGTCTGTCGTCTGC-3Ј and 5Ј-GGGCAGACGACAGACGTCTGACAAT-3Ј.
Oligonucleotides were annealed, radiolabeled with [␣-32 P]dCTP using Klenow DNA polymerase, and purified on Sephadex G-25 spin columns (Roche). Proteins were produced using a TNT T7coupled reticulocyte lysate system (Promega). DNA-binding assays were performed in gel shift binding buffer (Promega) in a total volume of 20 L using the indicated volumes of each protein and 2 L of labeled oligonucleotide at 50 000 cpm. The amount of reticulocyte lysate in each condition was constant. DNA-protein complexes were resolved on a 6% nondenaturing polyacrylamide gel, exposed to a Phosphor screen, and read in a PhosphorImager (Molecular Dynamics).
Hif2␣ Truncations
All truncations of Hif2␣ were generated by PCR and sequenceverified. Primer sequences are available on request.
Results
Tfap2␤ Is Expressed in DSM
We assayed Tfap2␤ mRNA expression in the embryonic mouse DA. At embryonic day (E)13.5, when remodeling of the outflow tract has occurred separating the pulmonary artery from the aorta, Tfap2␤ mRNA was strongly expressed in the DSM with sharp borders at the aortic and pulmonary artery ends ( Figure 1 ). Tfap2␤ expression was extinguished in mouse DSM by E18.5 and was not reinitiated after birth (Figure 1g through 1j) but was maintained in other neural crest derivatives (data not shown). We also assayed Tfap2␤ protein levels in mouse DSM by immunohistochemistry and found that protein levels correlated well with mRNA levels (Figure I in the online data supplement, available at http://circres.ahajournals.org).
Tfap2␤ Affects DSM Development
Mice lacking Tfap2␤ die shortly after birth and have delayed closure of the DA (B. Gelb, unpublished observation). Based on the early and transient expression of Tfap2␤, we hypothesized that loss of Tfap2␤ may result in a defect of embryonic DSM development. Histological analysis of hematoxylin/ eosin-stained sections of wild-type and Tfap2␤ Ϫ/Ϫ embryos harvested at E13.5, E15.5, or E18.5 ( Figure 2 ) revealed no difference in the morphology of DSM cells or in vascular wall thickness, nor did we observe differences in DA elastin deposition (supplemental Figure II) . To distinguish developing DSM, we examined expression of calponin, a marker of highly differentiated, contractile SMCs ( Figure 2 ). In both wild-type and Tfap2␤ Ϫ/Ϫ embryos from E13.5 through E15.5, radioactive in situ hybridization revealed higher levels of calponin mRNA expression in DSM than in the aorta or pulmonary artery (Figure 2g , 2h, 2k, and 2l). Preferential expression of calponin persisted at E18.5 in wild-type DSM (Figure 2o ) but was lost in Tfap2␤ Ϫ/Ϫ embryos, in which the level of calponin expression was similar in DSM and adjacent smooth muscle (Figure 2p ). These results indicate that, in the wild-type mouse, DSM likely matures earlier than aortic or pulmonary artery smooth muscle, consistent with previous reports on the developing human DA, 3 and suggest that Tfap2␤ may be necessary to maintain the highly differentiated state of DSM, although quantification of this difference is difficult.
Et-1 and Et A Are Expressed in DSM
To understand the mechanism underlying the DA closure defect in Tfap2␤ mutants, we examined other genes involved in ductal development. Because endothelin signaling is important for development and closure of the DA, we examined mRNA expression of Et A and its major ligand, Et-1, in the aortic arch of E13.5 mouse embryos. Et A was expressed in SMCs throughout the great vessels but did not uniquely mark DSM cells (Figure 3a ). Et-1 was expressed in endothelial cells throughout the developing vasculature, as expected. Surprisingly, Et-1 mRNA was also specifically expressed in DSM with distinct borders at the aortic and pulmonary artery junctions at E13.5 (Figure 3b ).
To determine whether mouse DSM expresses Et-1 perinatally, we examined Et-1 expression in the DA of E18.5 mouse embryos and in mice harvested at 15 or 30 minutes after birth (Figure 3c through 3e). By E18.5, the DSM expression of Et-1 was indistinguishable from background and was not reinitiated after birth, although endothelial expression remained. The DSM expression of Et-1 during development likely results in especially high levels of endothelin signaling in the DA that may distinguish the DA from other vessels and may contribute to the unique differentiation of DSM and the oxygen-sensitivity of DSM later at the time of parturition.
Hif2␣, a Potential Transcriptional Regulator of Et-1, Is Specifically Expressed in DSM During Development
Because Et-1 expression is, in part, regulated by an upstream Hif response element, 25 we examined the expression of the genes encoding Hif1␣, -2␣, and -3␣. At E13.5, Hif1␣ and Hif3␣ were ubiquitously expressed throughout the developing embryo (data not shown), whereas Hif2␣ was expressed primarily in vascular endothelial cells, as reported. 26 However, Hif2␣, like Et-1 and Tfap2␤, was expressed specifically in the DSM (Figure 4a ). Similar to Et-1, Hif2␣ expression declined in the DSM around birth but was maintained in the vascular endothelium (Figure 4b through 4d ).
To visualize Hif2␣ expression at higher resolution, we obtained E13.5 Hif2␣ ϩ/Ϫ embryos whose targeted allele contains a LacZ cassette. 21 LacZ expression in the Hif2␣ domain, shown by ␤-galactosidase activity, was at highest levels in the DA (Figure 4e ). Histological analysis of the outflow tract revealed that LacZ expression was restricted to vascular endothelial cells in most vessels but extended into the SMCs of the DA, consistent with the results of in situ hybridization for Hif2␣ mRNA (Figure 4f through 4h ). LacZ expression was not observed in any other SMCs of the embryo at this stage.
Tfap2␤ Is Required for DSM Expression of Hif2␣ and Et-1
Given the role of Tfap2␤ in DA development and coexpression with Hif2␣ and Et-1, we compared both Hif2␣ and Et-1 expression in wild-type and Tfap2␤ Ϫ/Ϫ mouse embryos to determine whether lack of Tfap2␤ would affect their expression. At E13.5 in Tfap2␤ Ϫ/Ϫ mouse embryos, Hif2␣ and Et-1 mRNA expression was lower in DSM of mutants compared to wild type ( Figure 5 ). Maintenance of endothelial expression of both genes provided an internal control for signal intensity and surrounding landmarks demonstrate comparable histological levels and angles. Because calponin expression was maintained in the absence of Tfap2␤, decreased Hif2␣ and Et-1 expression was not attributable to a lack of DSM cells in the Tfap2␤ Ϫ/Ϫ embryos. This result demonstrated a dependence on Tfap2␤ specifically for DSM enhancement of Hif2␣ and Et-1 expression.
Hif2␣ Regulates Et-1 in Vascular SMCs
Because Et-1 and Hif2␣ were specifically coexpressed in the DSM at E13.5, we investigated the possibility of an epistatic relationship between the 2 genes. An Hif response element (HRE) 118 bp upstream of the Et-1 transcription start site is required for hypoxic induction of Et-1 mRNA expression in cultured vascular endothelial cells. 27 Using this upstream region of the Et-1 locus to drive expression of luciferase, we performed reporter assays to test whether Hif2␣ was able to activate transcription through this HRE in SMCs ( Figure 6 ). All transfections were carried out with a mutant form of Hif2␣ that is not hydroxylated during normoxia, resulting in a stable form of the protein. Hif2␣ activated the reporter 6.5-fold in HUVECs, as expected. Hif2␣ also activated the reporter to a lesser extent in an A10 aortic SMC line and mutation of the HRE abolished this activation, indicating that Hif2␣ can act through the HRE to initiate transcription in cultured vascular SMCs ( Figure 6 ). However, in vivo, we were able to detect some Et-1 transcripts in DSM of Hif2␣ mutants before their death at E13.5, suggesting that other mechanisms may also regulate Et-1 at this stage (data not shown). 
Hif2␣ Blocks Transcriptional Activation by Tfap2␤ via the bHLH/PAS Domain
Because Hif2␣ and Tfap2␤ are both transcription factors enriched in DSM, we examined their potential synergistic or antagonistic interactions. Using a CAT reporter assay system, we found that Tfap2␤ could activate this reporter as described, 5 but cotransfection of Hif2␣ with Tfap2␤ blocked activation (Figure 7a) .
Because Tfap2␤ and Hif2␣ both rely on the transcriptional coactivator p300, negative regulation of Tfap2␤ by Hif2␣ could be explained by Hif2␣ sequestering p300. To test this idea, excess p300 was cotransfected with Tfap2␤, Hif2␣, or both. Although overexpression of p300 was able to enhance the transactivation potential of Tfap2␤, it could not rescue the negative regulation by Hif2␣, indicating that sequestration of p300 was not the mechanism by which Hif2␣ negatively regulated Tfap2␤ activity. Because the decreased activity could also be caused by a decrease in Tfap2␤ expression, we assayed Tfap2␤ protein in the cell lysates used in the reporter assay. Tfap2␤ protein was actually increased on coexpression with Hif2␣ and p300, and yet, Tfap2␤ transcriptional activity declined (Figure 7a ). Thus, Hif2␣ negatively regulated transactivation by Tfap2␤ independently of p300 sequestration or expression differences.
To determine which domains of Hif2␣ were responsible for its ability to block transcriptional activation by Tfap2␤, we generated Hif2␣ truncations (Figure 7c ) and tested them in the reporter assay described above (Figure 7b ). The amino terminus of Hif2␣ contains a bHLH domain, important for DNA binding and dimerization, and 2 PAS domain repeats whose functions are unknown. 26 The carboxyl terminus contains transcriptional activation domains. 28 Tfap2␤ activity was blocked by 386 residues of the amino terminus containing the bHLH and PAS domains (⌬C386), but deletion of half of the second PAS domain (⌬C281) resulted in failure to block Tfap2␤'s activity suggesting that the PAS domains are required for this function. Deleting as few as 131 residues (⌬N131) from the amino terminus of Hif2␣ also resulted in the loss of its ability to block transcriptional activation by Tfap2␤ (Figure 7b and 7c) . However, the PAS domains alone were not sufficient to elicit this effect, suggesting that the bHLH and PAS domains are required together. Western analysis of the cell lysates used to measure CAT protein levels revealed no significant difference in Tfap2␤ protein levels (data not shown), and immunocytochemical analysis showed that Hif2␣ mutants were appropriately localized to the nucleus (Figure 7d ). Thus, changes in Tfap2␤ expression or Hif2␣ localization were not responsible for the observed differences. Although we cannot rule out problems with protein folding, these results indicated that the bHLH/PAS domains of Hif2␣ were both necessary and sufficient to disrupt Tfap2␤-dependent reporter transactivation.
Hif2␣ Disrupts Tfap2␤-DNA Interaction
The negative regulation of Tfap2␤ by Hif2␣ could occur through 1 of at least 2 mechanisms: Hif2␣ could form a complex on DNA with Tfap2␤, thereby prohibiting transactivation by Tfap2␤; alternatively, Hif2␣ could disrupt DNA binding by Tfap2␤ altogether, thus preventing transactivation. To distinguish between these 2 possibilities, we performed electrophoretic mobility-shift assays with Tfap2␤ or Hif2␣ protein and an oligonucleotide containing a Tfap2 consensus binding site. Tfap2␤ specifically retarded oligonu- cleotide migration, but addition of Hif2␣ caused a dosedependent decrease in the amount of DNA bound to Tfap2␤ (Figure 8 ). We did not observe a supershift of the Tfap2␤-DNA complex arguing against a Tfap2␤-Hif2␣-DNA complex, repressing Tfap2␤. Thus, negative regulation of Tfap2␤ by Hif2␣ was likely attributable to a decrease of site-specific DNA binding by Tfap2␤ in the presence of Hif2␣. Because Tfap2␤ is required for DSM expression of Hif2␣, the negative feedback regulation of Tfap2␤ by Hif2␣ may allow finer control of Tfap2␤-dependent gene expression during development.
Discussion
This study shows that Tfap2␤, Hif2␣, and Et-1 are coexpressed in mouse DSM and that Tfap2␤ is necessary for proper DSM expression of both Hif2␣ and Et-1. Although DSM expression of Tfap2␤ occurs well before birth, we show that it is essential for the gene regulation associated with smooth muscle differentiation, suggesting a role for Tfap2␤ in development or maturation of DSM. Also, we found that Hif2␣ positively regulated Et-1 in cultured vascular SMCs but negatively regulated Tfap2␤ activity through inhibition of sequence-specific DNA binding by Tfap2␤. These data sug-gest a negative feedback loop through which Hif2␣ may titrate expression of Tfap2␤ target genes during DSM development.
Tfap2␤ and PDA
In humans, heterozygous mutations resulting in single amino acid substitutions within the DNA-binding or transactivation domains of TFAP2␤ are associated with Char syndrome and result in facial dysmorphism, PDA, and hand anomalies. 5, 6 These mutant forms of TFAP2␤ dimerize normally with other Tfap2 proteins causing dominant-negative effects. In contrast, targeted deletion of Tfap2␤ in mice results in a null mutation. Although the expression of other Tfap2 proteins in DSM and other tissues of Tfap2␤ Ϫ/Ϫ embryos has not been examined, compensation by the remaining Tfap2 family members may account for the reduced severity of Char syndrome characteristics in Tfap2␤ Ϫ/Ϫ pups, such as facial dysmorphism, which has not been noted, and hand anomalies, which occur with incomplete penetrance. 29 Interestingly, targeted deletion of smooth muscle myosin in mice, which prevents general smooth muscle contraction, results in postponement but not failure of DA closure, 30 whereas targeted deletion of several genes encoding elements of the prostaglandin pathway, including the receptor, EP 4 , and the cyclooxygenases, Cox-1 and Cox-2, results in PDA. [31] [32] [33] [34] The relatively early expression of Tfap2␤ in DSM led us to explore its role in DSM development, leaving the relationship of the Tfap2␤/Hif2␣/Et-1 developmental axis to genes encoding proteins important for oxygen sensing or DA constriction unknown. However, our data support the idea that earlier transcriptional events governed by Tfap2␤ activity may be important to prepare the DSM to respond to peripartum signals. For example, thickening of the subendothelial layer of the DA occurs during late gestation and may be a prostaglandindependent event stimulating migration of DSM cells, which is required for timely closure of the DA at birth. [35] [36] [37] 
Role of Et-1 and Hif2␣ in DSM Differentiation
Classical endothelin signaling occurs in a paracrine fashion: endothelial cells release endothelin ligands and bind their cognate receptors on the surface of neighboring SMCs, exerting a variety of effects, including proliferation. However, autocrine endothelin signaling can be stimulated in vitro and is uniquely associated with differentiation of vascular SMCs, rather than proliferation. 38 We have shown that DSM activates a unique transcriptional program under the influence of Tfap2␤, resulting in Et-1 expression. Given the role of Et-1 in smooth muscle differentiation, and its importance for delineation of neural crest-derived structures in general, it is possible that the DA defect in Tfap2␤ Ϫ/Ϫ mice is attributable, in part, to the downregulation of Et-1 in the DSM of these animals. Consistent with this, we have recently identified a heterozygous nonsense mutation in the gene encoding the endothelin receptor A in a patient with PDA (V. Garg and D. Srivastava, unpublished observation, 2003) . This mutation introduced a premature stop codon (S382X), not found in 300 control chromosomes, truncating the receptor and eliminating its cytoplasmic tail. A similar truncation renders the receptor nonfunctional in in vitro stud-ies, 39 but conclusive evidence of a role for Et-1 signaling in human PDA will require further genetic analyses.
Et-1 is expressed in the DSM of near-term fetal lambs, and its release depends on oxygen availability. 17 In mice, we found that Et-1 is not expressed perinatally within DSM, although it was highly expressed in endothelial cells throughout the great vessels. This may indicate a species-specific difference in the dependence on endothelin signaling during DA closure. However, both species may require Et-1 expression in DSM during development, not to induce constriction, but to pattern the neural crest-derived DSM in preparation for its physiological changes at birth.
Although a relationship between Hif2␣ and Et-1 is well established, our data suggest that the role of Hif2␣ in the DA includes refining the transactivation potential of Tfap2␤ by negatively regulating Tfap2␤-DNA binding. To date, neither Hif2␣ nor Tfap2␤ are known to directly control transcription of genes governing smooth muscle differentiation and determining the in vivo role of Hif2␣ in the DA beyond midgestation will await the development of the tissue-specific deletion of Hif2␣ in DSM.
Clinical Implications
Closure of the DA is vital for healthy extrauterine life. However, in the case of particular congenital heart defects that obstruct or disrupt blood flow to the lungs or body, DA patency is essential for systemic and pulmonary blood flow. Understanding the transcriptional regulation of normal DA development, maturation, and closure by factors such as Tfap2␤, Et-1, and Hif2␣, may provide additional targets for rational drug design to either close or open the DA, particularly in premature infants. Figure 8 . Hif2␣ blocks DNA binding by Tfap2␤. Electrophoretic mobility-shift assays were performed using in vitro transcribed and translated Tfap2␤ or Hif2␣ protein and a 32 P-labeled oligonucleotide containing a Tfap2-binding site; 100ϫ cold wild-type oligo (wt) competed for Tfap2␤ binding, whereas 100ϫ cold mutant oligo (mt) failed to compete, demonstrating sequencespecific binding to the probe by Tfap2␤. Hif2␣ failed to shift the probe but reduced the amount of oligo shifted in the presence of Tfap2␤ in a dose-dependent manner.
